Cidara Therapeutics Net Income From Continuing Ops Over Time
| CDTX Stock | USD 221.38 0.06 0.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cidara Therapeutics. Projected growth potential of Cidara fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cidara Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Cidara Therapeutics is measured differently than its book value, which is the value of Cidara that is recorded on the company's balance sheet. Investors also form their own opinion of Cidara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cidara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cidara Therapeutics' market value can be influenced by many factors that don't directly affect Cidara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cidara Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cidara Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cidara Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Cidara Therapeutics and related stocks such as Mineralys Therapeutics, Adaptive Biotechnologies, and Scholar Rock Holding Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (56.6 M) | (177.8 M) | (160 M) | (152 M) |
| ADPT | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (46.4 M) | (68.6 M) | (146.2 M) | (207.3 M) | (200.4 M) | (196 M) | (159.6 M) | (143.6 M) | (150.8 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (51 M) | (86.5 M) | (131.8 M) | (134.5 M) | (158.9 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (42 M) | (34.5 M) | (49.8 M) | (58.7 M) | (113 M) | (274.5 M) | (113.7 M) | (119.4 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (195.1 M) | (268.9 M) | (704.5 M) | (443.3 M) | (301 M) | (257.1 M) | (231.4 M) | (243 M) |
| BEAM | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (78.3 M) | (194.6 M) | (370.6 M) | (289.1 M) | (313.7 M) | (376.7 M) | (339.1 M) | (356 M) |
| CPRX | (6.4 M) | (6.4 M) | (4.1 M) | (12.2 M) | (15.5 M) | (20.2 M) | (18.1 M) | (18.4 M) | (34 M) | 31.9 M | 75 M | 39.5 M | 83.1 M | 62 M | 163.9 M | 188.5 M | 197.9 M |
| LEGN | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (133 M) | (303.5 M) | (386.2 M) | (446.3 M) | (509.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| IRON | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (71.9 M) | (46.8 M) | (64.1 M) | (109.4 M) | (98.4 M) | (103.3 M) |
| AGIO | (39.4 M) | (39.4 M) | (39.4 M) | (39.4 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (309.5 M) | (356.5 M) | (231.8 M) | (352.1 M) | 673.7 M | (412.8 M) | (433.4 M) |
Cidara Therapeutics and related stocks such as Mineralys Therapeutics, Adaptive Biotechnologies, and Scholar Rock Holding Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Cidara Therapeutics | CDTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6310 Nancy Ridge |
| Exchange | NASDAQ Exchange |
USD 221.38
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.